These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31863636)

  • 1. Covariate adjustment for randomized controlled trials revisited.
    Wang J
    Pharm Stat; 2020 May; 19(3):255-261. PubMed ID: 31863636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reduction.
    Keene ON
    Pharm Stat; 2019 Jan; 18(1):78-84. PubMed ID: 30370691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 4. The correlation between baseline score and post-intervention score, and its implications for statistical analysis.
    Clifton L; Clifton DA
    Trials; 2019 Jan; 20(1):43. PubMed ID: 30635021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment.
    Roger JH; Bratton DJ; Mayer B; Abellan JJ; Keene ON
    Pharm Stat; 2019 Jan; 18(1):85-95. PubMed ID: 30406948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian analysis of mortality outcomes in multicentre clinical trials in critical care.
    Sidebotham D; Popovich I; Lumley T
    Br J Anaesth; 2021 Sep; 127(3):487-494. PubMed ID: 34275603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model misspecification and robustness in causal inference: comparing matching with doubly robust estimation.
    Waernbaum I
    Stat Med; 2012 Jul; 31(15):1572-81. PubMed ID: 22359267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the variability of covariate adjustment. experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials.
    Lesaffre E; Bogaerts K; Li X; Bluhmki E
    Control Clin Trials; 2002 Apr; 23(2):127-42. PubMed ID: 11943440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis, Effect Modification, and Mediation.
    Vickers AJ; Steineck G
    Eur Urol; 2018 Sep; 74(3):243-245. PubMed ID: 29908877
    [No Abstract]   [Full Text] [Related]  

  • 10. A flexible multi-domain test with adaptive weights and its application to clinical trials.
    Zhao Y; Yu Q; Lake SL
    Pharm Stat; 2020 May; 19(3):315-325. PubMed ID: 31886602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.
    Kahan BC; Jairath V; Doré CJ; Morris TP
    Trials; 2014 Apr; 15():139. PubMed ID: 24755011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.
    Shin W; Kang SH
    J Biopharm Stat; 2016; 26(2):227-39. PubMed ID: 25372220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Segmented Regression and Difference-in-Difference Methods: Assessing the Impact of Systemic Changes in Health Care.
    Mascha EJ; Sessler DI
    Anesth Analg; 2019 Aug; 129(2):618-633. PubMed ID: 31008746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimum number of clusters and comparison of analysis methods for cross sectional stepped wedge cluster randomised trials with binary outcomes: A simulation study.
    Barker D; D'Este C; Campbell MJ; McElduff P
    Trials; 2017 Mar; 18(1):119. PubMed ID: 28279222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Friede T; Häring DA; Schmidli H
    Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new covariate adjustment methods for non-inferiority assessment of binary clinical trials data.
    Hou Y; Ding V; Li K; Zhou XH
    J Biopharm Stat; 2011 Jan; 21(1):77-93. PubMed ID: 21191856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures.
    Ouyang J; Zhang P; Carroll KJ; Lee J; Koch G
    J Biopharm Stat; 2020 Jul; 30(4):593-606. PubMed ID: 31829826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.